Gensia Treatment OKd
IRVINE — Gensia Laboratories Ltd., an Irvine maker and marketer of drug products, said Tuesday that it received federal approval for a new drug application that helps treat lung cancer.
Gensia received approval for an abbreviated new drug application for etoposide injection in polymer vials. Etoposide is an agent used in the treatment of patients with small-cell lung cancer and refractory testicular tumors.
“Etoposide is the second oncology product that we will supply in unique polymer packaging following the successful introduction of doxorubicin in this packaging format,” said Patrick D. Walsh, Gensia’s president.
Gensia is a wholly owned subsidiary of Gensia Inc., a San Diego medical research company.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
